

UNIVERSITY OF MARYLAND
DEPARTMENT OF RADIATION ONCOLOGY

SCHEDULE OF
PRESENTATIONS AND ACTIVITIES



Data to Dialogue: Communicating Radiotherapy's Value to Advance Care

2026 Annual Meeting
Boston, MA
September 26–30

All abstracts are available in the October 2026 [supplement](#) to the *International Journal of Radiation Oncology, Biology, Physics* (see Author Index, A5)

UNIVERSITY OF MARYLAND
DEPARTMENT OF RADIATION ONCOLOGY
WELCOME DINNER RECEPTION

Sunday, September 27; 6:30–9:30 PM
Davio's Boston Seaport; 26 Fan Pier
Boston, MA

SATURDAY, SEPTEMBER 26 SCAROP MEETING

4:00–5:00 PM ROOM 256 ORAL
Preliminary Review of SCAROP Funds Flow Part One Survey Results
Regine W

SUNDAY, SEPTEMBER 27 PRESENTATIONS

11:00 AM–3:30 PM ROOM 153 SESSION CHAIR
ASPP Aspiring Scientists and Physicians program headed by the Workforce Diversity Committee,
subcommittee of the HACE Council
Vyfhuis M

11:05 AM–12:00 PM ROOM 153 PANEL PARTICIPANT
Career Pathways in Radiation Oncology
Guerrero M

4:00–5:00 PM EXHIBIT HALL A POSTER
Implementing guideline-directed hypofractionation at a satellite academic radiation oncology center
Rana Z, Scott J, Youssef A, Citron W, Kim M, Molitoris J, Zhou J, Manandhar B, Douglass L, Murphy A,
Larrimore P, Woolsey L, Allen S, Tafia T, Ferski M, Windsor G, Adams B, Leverage J, Gerrity M, Young F,
McAvoy S, Nichols E, Regine W, Mishra M

4:00–5:00 PM EXHIBIT HALL A POSTER
Proton vs. photon radiotherapy for patients with oropharyngeal cancer in the USA: A cost-effectiveness
analysis.
Hemmati M, Toumazis I, Lee JJ, Janbeh Saray SMM, Ning MS, Foote RL, Busse PM, Rosenthal DI, Garden
AS, Patel SH, Snider JW III, Gunn GB, Molitoris JK, Ma DJ, Parvathaneni U, Shah SJ, Lin A, Lee NY,
McDonald MW, Kalman NS, Katz SR, Bajaj GK, Henson C, Dagan R, Hernandez M, Swanson D, Morrison
WH,7 Fuller CD, Phan J, Moreno AC, Lee A, Spiotto MT, Mayo LL, Liao JJ, Paly JJ

MONDAY, SEPTEMBER 28 PRESENTATIONS

8:00–9:00 AM ROOM 258 SESSION MODERATOR
Predicting outcomes in breast cancer: From multi-omics to AI-driven models
Nichols E

8:20–8:25 AM ROOM 258 QUICK PITCH ORAL
Comparable cosmetic outcomes across racial and age groups after dose-escalated five-fraction stereotactic
partial breast irradiation (S-PBI) on a phase II multicenter trial
Bolton C, Fattah K, Kim DWN, Leitch M, Parsons DDM, Nichols EM, Lu W, Becker SJ, Alluri PG,
Nwachukwu CR, Ahn C, Chiu TD, Farr D, Wooldridge R, Bahr S

10:45–12:00 AM EXHIBIT HALL A POSTER
Fetal neutron dose reduction by a novel planning modification in proton pencil beam scanning
Rahimi R, Griffin KT, Alicia D, Shin J, Nichols EM, Ferris MJ, Lee ??, Yi BY

MONDAY, SEPTEMBER 28 PRESENTATIONS (CONTINUED)

10:45–12:00 AM EXHIBIT HALL A POSTER*

Validating dual oxygenase 2 as a modulator of radiosensitivity and expression of the immune checkpoint program death-ligand 1 (PD-L1) in esophageal cancer

Allen AJ, Martins M, Azarbarzin S, Molitoris J, Carrier F

*Presidential poster award

10:45 AM–12:00 NOON EXHIBIT HALL A POSTER*

Investigating a potential prophylactic role eFLASH in a murine lung metastatic soft-tissue sarcoma model

Khamis Y, Ng VY, Byrne K, Poirier Y, Pandey S, Shukla H, Newman D, Tighe K, Ma X, Carter-Cooper B, Casildo A, Azarbarzin S, Richard K, Regine W, Carrier F

*Also part of Presidential Science Session, September 28, 4:00-5:00 PM

10:45 AM–12:00 NOON EXHIBIT HALL A POSTER

Pre-treatment multi-sequence MRI radiomics for predicting pathologic complete response in sarcoma patients treated by radiation therapy

Moradmand H, Olabumuyi A, Brown M, Allen A, Manuel E, Nwilo A, Kunaprayoon D, Regine W, Molitoris J, Ren L

10:45 AM –12:00 NOON EXHIBIT HALL A POSTER

Chemical validation of the role of caveolin-1 as a biomarker for chemoradiation resistance in non-small cell lung cancer

Pyo D, Carrier F, Shukla H, Roy S, Kunaprayoon D

11:05–11:15 AM ROOM 109 ORAL

Estimating neurocognitive failure in the presence of competing mortality: Kaplan-Meier and competing-risk analyses from NRG CC001

Zarinshenas R, Sun K, Cherng HRR, Bentzen SM, Mishra MV

1:47–1:56 PM GRAND BALLROOM ORAL, PLENARY

Initial results of NRG Oncology NRG-GI003: A phase III randomized trial of protons versus photons for hepatocellular carcinoma (HCC) (NCT03186898)

Hong T, Winter K, Koay E, Kilcoyne A, Franses J, Wolfgang J, Sohn J, Kachnic L, Duda D, Wo J, Roberts H, Ludmir E, Noticewala S, Kharofa J, Molitoris J, Patel P, Thompson A, Kabaritti R, Pitter K, Crane C

2:21–2:30 PM GRAND BALLROOM ORAL, PLENARY

NRG-CC009: A phase III trial of stereotactic radiosurgery (SRS) vs. hippocampal-avoidant whole brain radiotherapy (HA-WBRT) for brain metastases from small cell lung cancer (SCLC)

Rusthoven CG, Paulus R, Gondi V, Brown PD, Camidge DR, Bovi JA, Palmer JD, Wefel JS, Loughan A, Grosshans DR, Mishra MV, Shah SA, Tome WA, Wenzel J, Zhu S, Cramer CK, Huang AJ, Thibault I, Pugh S, Kachnic LA

3:00–4:00 PM EXHIBIT HALL A POSTER

Predictors of heterotopic ossification after acetabular fixation: secondary analysis of a randomized trial of prophylactic radiation

Hoover T, Bentzen S, Sun K, Boissonneault A, O'Hara N, Slobogean G, Sciadini M, Nascone J, Gage M, Lin J, O'Toole R, Mishra M

3:00–4:00 PM EXHIBIT HALL A POSTER

Risk factors for high-grade dermatitis following breast/chest wall and regional nodal irradiation with proton beam radiotherapy: Results of a multi-institutional prospective registry trial

Valenzuela D, Bhatti AA, Rao AD, Chawla AK, Majithia L Jr, Hetelekidis S, Gao S, Kowalski ES, Marqueen KE, Bajaj GK, Nichols EM, Simone CB II, Choi IJ

3:10–3:15 PM ROOM 254 QUICK PITCH ORAL

The influence of cancer primary site on outcomes after preoperative radiosurgery for resected brain metastases: A XXX international multicenter cohort study

Prabhu RS, Russek R, Vaslow ZK, Matsui JK, Haghighi N, Dan T, Mishra MV, Murphy ES, Boyles S, Perlow HK, Palmer JD, Udovicich C, Patel T, Wardak Z, Woodworth GF, Ksendzovsky A, Yang K, Chao ST, Asher A, Burri SH

TUESDAY, SEPTEMBER 29 PRESENTATIONS

12:30–1:45 PM EXHIBIT HALL A POSTER

Prospective study assessing C-arm linac high-performance CBCT for reliable target and OAR contouring
Cammin J, Chen J, Zarinshenas R, Khamis Y, Olabumuyi A, Armstrong P, Nwiloh A, Sawant A, Molitoris J

12:30–1:45 PM EXHIBIT HALL A POSTER

Comparison of delivery-based strategies for reducing voxel-wise dose rate in pencil beam scanning proton therapy
Herschbach D, Kwok Y, Chen S, Regine W, Mishra M, Mossahebi S

12:30–1:45 PM ROOM 258 ORAL

Clinical integration of a novel snout-mounted quad-camera prompt gamma imaging system for in vivo proton range verification

Safavi F, Peterson S, Mossahebi S, Sharma V, Chalise A, Shakeri E, Lewis H, Gobbert M, Polf J, Ren L

12:30–1:45 PM EXHIBIT HALL A POSTER

Assessing the generalizability and robustness of deep-learning dose prediction in head-and-neck radiotherapy to clinically realistic CT perturbations

Tripathi N, Chowdhury R, Ren L, Sawant A, Vaishnav B

12:30–1:45 PM EXHIBIT HALL A POSTER

Modeling radiotherapy and chemotherapy response using pancreatic tumor organoids

Yang C, Keepers Z, Shukla HD, Ren L

12:40–12:50 PM ROOM 210 ORAL

The role of docetaxel in addition to salvage radiation and androgen deprivation in men with high-risk prostate cancer post-prostatectomy: Results of NRG GU002

Hurwitz M, Johnson T, Sartor AO, Kelly WK, Lee CT, Xiao Y, Dess RT, Michalski JM, Mao SS, Gunter T, Dicker A, Mishra MV, Scroggins TG Jr, Parthasarathy A, Bott-Kothari TL, Valogh A, Pugh S, Nguyen PI, Sandler HM

12:55–1:00 PM EXHIBIT HALL A QUICK PITCH ORAL

A precision medicine navigator can mitigate disparities associated with utilization of genomic tests: A multi-institutional review

Clark J, Tseng HW, Chang JH, Shamsuddin Z, Jack Y, Allen AJ, Datnow-Martinez C, Eggleston C, Ferris MJ, Rana ZH, Shah SJ, Rooney MK, Tang C, Hassanzadeh CJ, Regine WF, Kwok Y, Tran PT, Vyfhuis MAL, Choi S, Molitoris JK

2:15–3:30 PM EXHIBIT HALL A POSTER

Toxicity outcomes and patterns of failure after whole vs. partial gland HDR brachytherapy as salvage treatment for recurrent prostate cancer

Armstrong P, Kiguru N, Olabumuyi A, Molitoris J, Lamichhane N, Xu J, Guerrero M, Cammin J, Mossahebi S, Rana Z, Kim M, Kudryasheva S, Naslund M

2:15–3:30 PM EXHIBIT HALL A POSTER

Radiomic analysis of pretreatment PSMA PET/CT for prognostic stratification in patients with oligometastatic castration sensitive prostate cancer

Cao Y, Sutura P, Mendes W, Jiang Z, Sawant A, Marchioni L, Simone NL, Tran PT, Onal C, Ren L

2:15–3:30 PM EXHIBIT HALL A POSTER

Comparison of urinary toxicity in prostate cancer patients undergoing external beam radiation therapy with high-dose vs. low-dose brachytherapy boost

Drovetsky C, Guerrero M, Cammin J, Lamichhane N, Xu J, Mossahebi S, Kudryasheva S, Morris B, Foard A, Rana Z, Kim M, Naslund M, Molitoris J

TUESDAY, SEPTEMBER 29, PRESENTATIONS (CONTINUED)

2:15–3:30 PM EXHIBIT HALL A POSTER

Phase I dose-escalation of hypofractionated pelvic nodal proton radiotherapy with simultaneous integrated prostate boost

Khamis Y, Sun K, Eggleston C, Patel A, Rana Z, Kunaprayoon D, Straub E, Kwok Y, Molitoris J, Bentzen S, Mishra M

2:15–3:30 PM EXHIBIT HALL A POSTER

Evaluation of proton beam radiotherapy in ovarian cancer: Analysis of the multicenter Proton Collaborative Group Prospective Registry

Padmanabhan R, Yacoub I, Chhabra AM, Choi IJ, Tang J, Marshall DC, Bloom JR, Gupta V, Lin LL, James SE, Thukral AD Jr, Nichols EM, Zeng J, Vargas CE, Alektiar KM, Mehta KJ, Simone CB II, Hsieh K

2:35–2:45 PM ROOM 253 ORAL

Early prediction of local recurrence after SBRT in non-small cell lung cancer using CT-based imaging biomarkers and clinical factors

Singh A, Allen AJ, Hamza M, Valluri S, Cherng HR, Assif J, Rana Z, Ren L

3:45–5:00 PM EXHIBIT HALL A POSTER

Beyond prescription dose: Target coverage and volume extremes predict local control after lung SBRT

Allen AJ, Ferris F, Vyfhuis M, Hamza M, Cherng HR, Assif J, Eggleston C, Marter K, Krudys K, Gahagan C, McAvoy S, Molitoris J, Mohindra P, Rana Z

3:45–5:00 PM EXHIBIT HALL A POSTER

Genomic analysis of clinical outcomes in p16-positive oropharyngeal cancer and identification of low frequency high-risk mutations

Brown M, Song Y, Thompson A, Valluri S, Rajabi Abhari D, Shetty A, Mendes W, Mehra R, Hatten K, Taylor R, Moyer K, Wolf J, Tyer T, Steacy K, Eggleston C, Datnow-Martinez C, Gaykalova D, Ferris M, Molitoris J, Tran P

3:55–4:05 PM ROOM 210 ORAL

Genomic stratification of benefit from short-term androgen deprivation with dose-escalated radiotherapy in intermediate-risk prostate cancer: An ancillary study of NRG/RTOG 0815

Jia AY, Johnson M, Proudfoot J, Davicioni E, Rana ZH, Seibert TM, Spratt DE, Simko J, Citrin DE, Martinez AA, Gore EM, El-Gayed A, Michalski JM, Raben A, Lee SPH, Efstathiou JA, Karrison TG, Johnson T, Tran PT, Krauss DJ

3:55–4:05 PM ROOM 253 ORAL

Association of baseline cardiac risk factors, patient and treatment variables with cardiac adverse events (AE) for early-stage breast cancer patients on NRG Oncology RTOG 1005 (NRG/R1005) Clinical Trial

White JR, Winte K, Vicin FA, Freedman GM, Woodward WA, Xiao Y, Stearns V, Safder T, Geng H, Arthur DW, Taghian AG, Lyons J, Tomberlin JK, Seaward SA, Cheston S, Anderson BM, Perera FE, Shumway D, Poppe MM, Mamounas EP

4:35–4:45 PM ROOM 210 ORAL

Interpreting the model: Biologic pathways underlying a clinically validated multimodal digital pathology AI biomarker in metastatic prostate cancer

Sutera P, Shetty A, Song Y, Mendes A, Yamashita R, Stewart E, Showalter TN, Berlin A, Kiess AP, Song D, Supiot S, Dirix PRP, Mercier C, Onal HC, Ost P, Kagohara LT, Lotan TL, Zhao SG, Deek MP, Tran PT

5:20–5:25 PM ROOM 254 QUICK PITCH ORAL

End-of-life ethics consultations in radiation oncology: An analysis of decision-making, medical futility, and goals of care

McGinnis PJ, Brough T, Balaji A, Keepers Z, Olabumuyi A, Silverman H

WEDNESDAY, SEPTEMBER 30, PRESENTATIONS

9:30–9:35 AM

ROOM 254

QUICK PITCH ORAL

Somatic genetic variants as predictors for radiation-induced short and long-term toxicity in head and neck cancers
Thompson AD, Brown MH, Song Y, Rajabi Abhari D, Valluri SS, Shetty A, Mendes W, Mehra R, Hatten K, Taylor R, Moyer KF, Wolf JS, Tyler TN, Steacy K, Eggleston C, Datnow-Martinez C, Gaykalova D, Tran PT, Ferris MJ, Molitoris JK.

10:45–11:45 AM

ROOM 153

SESSION MODERATOR

AI powered dose prediction and segmentation
Ren L

10:45–11:45 AM

ROOM 160

SESSION MODERATOR

Imaging for planning
Sawant A